ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer
Study designed to investigate the efficacy and safety of ISA101b…
30 November 2022/by LRuasNXI Therapeutics Press Release NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
Experienced life sciences executive Dr Ruben Herrendorff…
30 November 2022/by LRuasBiocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
STIMULAN® gives surgeons the freedom to choose and combine the…
29 November 2022/by Marketing TeamWe’d love to hear from you
For more information about optimum Strategic Communications, please get in touch
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer
/in Client newsNXI Therapeutics Press Release NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
/in Client newsBiocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
/in Client newsSTORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
/in Client newsImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences
/in Client news